James Peyer, Cambrian BioPharma CEO

Ex­er­cise in a pill? That's the fo­cus of Cam­bri­an's new pipeline com­pa­ny

In line with its an­ti-ag­ing cen­tral theme, Cam­bri­an Bio­Phar­ma has a new clin­i­cal can­di­date to work with, go­ing af­ter what CEO James Pey­er de­scribed as a “Holy Grail tar­get.”

The New York drug de­vel­op­er an­nounced the launch of its newest pipeline com­pa­ny, Am­pli­fi­er Ther­a­peu­tics, Tues­day morn­ing. Cam­bri­an is in­vest­ing $26 mil­lion in­to Am­pli­fi­er to kick things off, Pey­er told End­points News. James Hall, the ex-head of car­dio­vas­cu­lar BD at As­traZeneca, is at the helm as Am­pli­fi­er’s CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.